aod9604 clinical trials weight loss kg trial fat evidence loss isn't one process. It's three. And scientists The effect of a single – Detection and in vitro metabolism

Are primarily trying to lose weight on the scale: Tesamorelin shifts body composition

Comparison AOD-9604 vs Semaglutide: Fat Loss Peptide Head-to-Head Comparison AOD-9604 failed Phase 2 (no significant fat loss)

Standard AOD-9604 Dosing Protocol Typical Dosing Range: Standard Dose: 250-500 mcg per day Clinical Trial Dose: 1 mg (1,000 mcg) per day (most effective in studies) Conservative Start: 250 mcg per day for first week Maintenance Range: 500 mcg per day for sustained protocols Frequency: Once daily, typically before breakfast Timing Rationale: Morning fasted state maximizes fat oxidation potential Cycle Length: 12-24 weeks for body composition protocols Administration Route: Subcutaneous injection (abdomen, thigh, or upper arm) Reconstitution: Bacteriostatic water, standard peptide protocols Note: Clinical trials used oral formulations, but subcutaneous administration is more common in current use due to improved bioavailability

Subjective tracking Energy levels, particularly during fasted states, often improve with effective AOD-9604 protocols

International Journal of Obesity, 25(10), 1442-1449

Not a medicine, not evaluated by BPOM, and not for human or veterinary consumption